Faruqi & Faruqi, LLP is investigating claims against Aquestive Therapeutics for allegedly misleading investors about the status of its NDA for Anaphylm. The company reportedly concealed problems related to the use and labeling of its sublingual film product, leading to a significant stock price drop of 37% on January 9, 2026. Investors who bought Aquestive securities between June 16, 2025, and January 8, 2026, are encouraged to consider joining the class action before the May 4, 2026 deadline. The law firm is also seeking whistleblowers and others with information about Aquestive's conduct to come forward.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
